Achillion Pharma, Too Much of a Good Thing After 50% Gain? (ACHN, MRK, GILD, VRUS, BMY, INHX, VRTX)
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) has been on fire due to the rapid interest of hepatitis C treatments and the bidding of players in the sector. With Merck & Co. (NYSE: MRK) driving further…